Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results
- €115 million out-licensing agreement
- Positive data from European confirmatory trial (PAES)
Lund, Sweden, 22 July 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its half year report for the period January-June 2026.
